← 返回

敲低 Xkr8 通过调节肿瘤免疫微环境增强化疗疗效

英文原题:Knocking down of Xkr8 enhances chemotherapy efficacy through modulating tumor immune microenvironment.

查看英文原题

Knocking down of Xkr8 enhances chemotherapy efficacy through modulating tumor immune microenvironment.

PubMed 2024/03/10(内容时间) J Control Release Q1 · IF 12.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

Scramblase Xkr8 在凋亡过程中调控磷脂酰丝氨酸(PS)的外化,并在促进肿瘤免疫抑制中发挥关键作用。靶向 Xkr8 联合化疗展现出增强抗肿瘤免疫应答并克服化疗-免疫抵抗的新途径。

在此,我们通过使用临床相关的原位模型进一步评估了该策略,并通过深入的单细胞 RNA 测序(scRNA-seq)阐明了其机制。

我们发现,Xkr8 敲低通过阻碍凋亡细胞的正常清除,展现出导致免疫原性细胞死亡(ICD)的潜力。Xkr8 小干扰 RNA(siRNA)与化疗前药 FuOXP 的共递送在原位胰腺肿瘤模型中显示出显著的治疗效果,肿瘤微环境(TME)中增殖性 NK 细胞和活化巨噬细胞浸润增加。单细胞轨迹分析进一步揭示,联合治疗后肿瘤浸润 CD8+ T 细胞优先向细胞毒性表型而非耗竭表型分化。

我们的研究为 Xkr8 敲低对 TME 的影响提供了新的见解,并巩固了将 Xkr8 敲低与化疗联合用于治疗多种类型癌症的理论基础。

展开英文摘要原文

Scramblase Xkr8 regulates the externalization of phosphatidylserine (PS) during apoptosis and holds a pivotal role in fostering tumor immunosuppression. Targeting Xkr8 in conjunction with chemotherapy demonstrated a novel avenue for amplifying antitumor immune response and overcoming chemo-immune resistance.

Here we further evaluated this strategy by using a clinically relevant orthotopic model and elucidated the mechanism through in-depth single-cell RNA sequencing (scRNA-seq).

We found that Xkr8 knockdown exhibited the potential to lead to immunogenic cell death (ICD) by impeding the normal clearance of apoptotic cells. Co-delivery of Xkr8 small interference RNA (siRNA) and chemo prodrug FuOXP showed remarkable therapeutic efficacy in an orthotopic pancreatic tumor model with an increase of proliferative NK cells and activated macrophages infiltration in the tumor microenvironment (TME).

Single-cell trajectory analysis further unveiled that tumor infiltrating CD8 + T cells are differentiated favorably to cytotoxic over exhausted phenotype after combination treatment.

Our study sheds new light on the impact of Xkr8 knockdown on TME and solidifies the rationale of combining Xkr8 knockdown with chemotherapy to treat various types of cancers.

论文信息

作者
Chen Y、Chen CY、Huang H、Luo Z、Mu Y、Li S、Li S
第一作者单位
Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.United States
通讯作者单位
Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: sol4@pitt.edu.United States
期刊
Journal of controlled release : official journal of the Controlled Release Society2024 Mar 10
原文标识
PubMed 38471639 · DOI 10.1016/j.jconrel.2024.03.011